The Medtronic Linq and Linq II implantable cardiac monitors (ICM) have become some of the most popular ICM devices on the market, partly because they are easy to insert.

In a recent interview with Cardiovascular Business, ACC President Edward T. A. Fry, MD, discussed some of the healthcare disparities that were highlighted during the COVID-19 pandemic. 

Ty Gluckman, MD, explains the main points of the American College of Cardiology (ACC) expert consensus on the cardiovascular consequences stemming from a COVID-19 infection.

Fry joined us for an exclusive interview, discussing lessons learned during the pandemic, some key ways to address physician burnout and much more. 

Learn more about the late-breaking studies presented at ACC.22 in Washington, D.C. 

Michael J. Reardon, MD, professor of cardiothoracic surgery and Allison Family Distinguished chair of cardiovascular research at Houston Methodist DeBakey Heart and Vascular Center, presented pooled data at ACC.22 from the CoreValve SURTAVI trials that found transcatheter aortic valve replacement (TAVR) was more durable than surgical aortic valve replacement (SAVR) devices.

Adam Greenbaum, MD, co-director of the Structural Heart and Valve Center at Emory University Hospital Midtown in Atlanta, explains details from the late-breaking CLASP TR trial at ACC.22.

Several late-breaking clinical trials at ACC.22 will likely impact clinical practice. Below are summaries of a few key trials and their takeaways for interventional cardiology and structural heart interventions.